ArticleMolecular biology reports2026
Quercetin ameliorates rheumatoid arthritis-associated bone erosion via inhibiting the Wnt3a/β-catenin signaling axis.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundAberrant activation of the Wnt3A/β-catenin pathway is critically involved in the bone erosion of rheumatoid arthritis (RA). The natural flavonoid quercetin (QUE) ameliorates RA symptoms, but its mechanistic link to this pathway is poorly understood. This study investigated whether QUE attenuates bone destruction in collagen-induced arthritis (CIA) rats by inhibiting Wnt3A/β-catenin signaling. CIA rats were treated with QUE or methotrexate (MTX) for 28 days, and bone destruction, inflammatory cytokines, and the expression of Wnt3A/β-catenin were systematically assessed.
resultsCompared with normal rats, CIA rats exhibited significantly increased arthritis scores, hind paw volume, and pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-17 A), alongside decreased bone mass parameters (BMD, BV/TV, Tb.Th, Tb.N) and severe joint damage. Notably, Wnt3A and β-catenin were markedly upregulated in the spleen and joints. QUE intervention effectively reversed these changes: it alleviated clinical symptoms, improved bone microarchitecture, restored cytokine balance, and substantially downregulated the mRNA and protein expression of Wnt3A and β-catenin. The improvements in bone microarchitecture were comparable to those achieved with MTX. Importantly, QUE did not induce hepatorenal toxicity.
conclusionsThese findings suggest that quercetin may protect against arthritic bone erosion at least in part by suppressing the Wnt3A/β-catenin pathway and coordinately regulating inflammatory-osteolytic coupling to attenuate synovitis and improve bone microarchitecture without observable toxicity. They also support its potential as a safe, disease-modifying agent for RA management, although further studies are needed to establish the direct causal relationship.
Indexed as
Identifiers
42742793What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.